vs
EVERTEC, Inc.（EVTC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
EVERTEC, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$244.8M vs $207.3M），EVERTEC, Inc.净利率更高（15.1% vs -62.0%，领先77.1%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 13.1%），EVERTEC, Inc.自由现金流更多（$63.7M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 9.2%）
EVERTEC Inc.是总部位于波多黎各的领先全品类支付技术与交易处理服务商，主要面向拉丁美洲及加勒比地区的金融机构、零售商户和政府客户，提供商户收单、电子资金转账、数字支付解决方案及业务流程外包服务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EVTC vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $244.8M | $207.3M |
| 净利润 | $37.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 17.6% | -54.7% |
| 净利率 | 15.1% | -62.0% |
| 营收同比 | 13.1% | 25.9% |
| 净利润同比 | -8.9% | 3.5% |
| 每股收益（稀释后） | $0.57 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $244.8M | $207.3M | ||
| Q3 25 | $228.6M | $159.9M | ||
| Q2 25 | $229.6M | $166.5M | ||
| Q1 25 | $228.8M | $139.3M | ||
| Q4 24 | $216.4M | $164.6M | ||
| Q3 24 | $211.8M | $139.5M | ||
| Q2 24 | $212.0M | $147.0M | ||
| Q1 24 | $205.3M | $108.8M |
| Q4 25 | $37.0M | $-128.6M | ||
| Q3 25 | $32.9M | $-180.4M | ||
| Q2 25 | $40.5M | $-115.0M | ||
| Q1 25 | $32.7M | $-151.1M | ||
| Q4 24 | $40.7M | $-133.2M | ||
| Q3 24 | $24.7M | $-133.5M | ||
| Q2 24 | $31.9M | $-131.6M | ||
| Q1 24 | $16.0M | $-170.7M |
| Q4 25 | 17.6% | -54.7% | ||
| Q3 25 | 16.5% | -106.9% | ||
| Q2 25 | 24.4% | -64.8% | ||
| Q1 25 | 21.6% | -102.6% | ||
| Q4 24 | 22.2% | -74.3% | ||
| Q3 24 | 19.6% | -94.6% | ||
| Q2 24 | 20.5% | -79.1% | ||
| Q1 24 | 16.0% | -151.9% |
| Q4 25 | 15.1% | -62.0% | ||
| Q3 25 | 14.4% | -112.8% | ||
| Q2 25 | 17.6% | -69.0% | ||
| Q1 25 | 14.3% | -108.5% | ||
| Q4 24 | 18.8% | -80.9% | ||
| Q3 24 | 11.7% | -95.7% | ||
| Q2 24 | 15.0% | -89.5% | ||
| Q1 24 | 7.8% | -156.8% |
| Q4 25 | $0.57 | $-1.28 | ||
| Q3 25 | $0.51 | $-1.81 | ||
| Q2 25 | $0.62 | $-1.17 | ||
| Q1 25 | $0.50 | $-1.57 | ||
| Q4 24 | $0.62 | $-1.34 | ||
| Q3 24 | $0.38 | $-1.40 | ||
| Q2 24 | $0.49 | $-1.52 | ||
| Q1 24 | $0.24 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $306.0M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $621.6M | $-80.0M |
| 总资产 | $2.2B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $306.0M | $421.0M | ||
| Q3 25 | $474.7M | $202.5M | ||
| Q2 25 | $290.6M | $176.3M | ||
| Q1 25 | $265.9M | $127.1M | ||
| Q4 24 | $273.6M | $174.0M | ||
| Q3 24 | $275.4M | $150.6M | ||
| Q2 24 | $257.7M | $480.7M | ||
| Q1 24 | $293.7M | $112.3M |
| Q4 25 | $621.6M | $-80.0M | ||
| Q3 25 | $663.8M | $9.2M | ||
| Q2 25 | $612.3M | $151.3M | ||
| Q1 25 | $542.1M | $144.2M | ||
| Q4 24 | $472.5M | $255.0M | ||
| Q3 24 | $502.6M | $346.8M | ||
| Q2 24 | $483.4M | $432.4M | ||
| Q1 24 | $507.3M | $140.3M |
| Q4 25 | $2.2B | $1.5B | ||
| Q3 25 | $2.1B | $1.2B | ||
| Q2 25 | $2.0B | $1.3B | ||
| Q1 25 | $1.9B | $1.3B | ||
| Q4 24 | $1.9B | $1.5B | ||
| Q3 24 | $1.9B | $1.5B | ||
| Q2 24 | $1.9B | $1.6B | ||
| Q1 24 | $2.0B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $70.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $63.7M | $-100.8M |
| 自由现金流率自由现金流/营收 | 26.0% | -48.6% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.89× | — |
| 过去12个月自由现金流最近4个季度 | $203.7M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $70.0M | $-99.8M | ||
| Q3 25 | $70.9M | $-91.4M | ||
| Q2 25 | $48.5M | $-108.3M | ||
| Q1 25 | $37.6M | $-166.5M | ||
| Q4 24 | $75.2M | $-79.3M | ||
| Q3 24 | $53.6M | $-67.0M | ||
| Q2 24 | $90.6M | $-77.0M | ||
| Q1 24 | $40.7M | $-190.7M |
| Q4 25 | $63.7M | $-100.8M | ||
| Q3 25 | $65.3M | $-92.7M | ||
| Q2 25 | $43.5M | $-110.7M | ||
| Q1 25 | $31.2M | $-167.8M | ||
| Q4 24 | $70.8M | $-79.5M | ||
| Q3 24 | $49.7M | $-68.6M | ||
| Q2 24 | $78.8M | $-79.0M | ||
| Q1 24 | $35.3M | $-193.9M |
| Q4 25 | 26.0% | -48.6% | ||
| Q3 25 | 28.5% | -58.0% | ||
| Q2 25 | 18.9% | -66.5% | ||
| Q1 25 | 13.7% | -120.5% | ||
| Q4 24 | 32.7% | -48.3% | ||
| Q3 24 | 23.5% | -49.2% | ||
| Q2 24 | 37.2% | -53.7% | ||
| Q1 24 | 17.2% | -178.2% |
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 2.5% | 0.8% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 2.8% | 1.0% | ||
| Q4 24 | 2.0% | 0.1% | ||
| Q3 24 | 1.8% | 1.2% | ||
| Q2 24 | 5.6% | 1.4% | ||
| Q1 24 | 2.6% | 3.0% |
| Q4 25 | 1.89× | — | ||
| Q3 25 | 2.16× | — | ||
| Q2 25 | 1.20× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 1.85× | — | ||
| Q3 24 | 2.17× | — | ||
| Q2 24 | 2.84× | — | ||
| Q1 24 | 2.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVTC
| Latin America Payments And Solutions | $101.5M | 41% |
| Business Solutions | $58.3M | 24% |
| Merchant Acquiring Net | $48.2M | 20% |
| Payment Services Puerto Rico Caribbean | $36.8M | 15% |
| Transferred At Point In Time | $4.0M | 2% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
